As such, targeting ENO2 and its interactions with HIF-1α could potentially offer novel therapeutic avenues for ccRCC treatment by exploiting the vulnerabilities that arise from metabolic adaptations. Here, ENO2 is linked to nonpapillary renal cell carcinoma.